PolyBio Research Foundation
@polybiorf.bsky.social
501(c)3 transforming how #LongCovid, #ME/CFS & Lyme+ are studied, diagnosed, and treated. Leading the #LongCovid Research Consortium.
Pinned
1/ Introducing PolyBio’s new interactive website module, where you can learn about our #LongCovid Research Consortium projects, technologies, and findings across international institutions:
polybio.org/consortium-p...
polybio.org/consortium-p...
This work is expanding how we think about Alzheimer’s disease, which is increasingly tied to the activity of pathogens that can infect the CNS. PolyBio is excited to be growing our program on infectious contributions to Alzheimer’s in 2026. (2/2)
February 9, 2026 at 10:30 PM
This work is expanding how we think about Alzheimer’s disease, which is increasingly tied to the activity of pathogens that can infect the CNS. PolyBio is excited to be growing our program on infectious contributions to Alzheimer’s in 2026. (2/2)
PolyBio scientific advisory board member Dr. William Eimer led the recent discovery of beta-amyloid & tau proteins’ antimicrobial activity targeting Herpes Simplex Virus 1 in the brain. (1/2)
February 9, 2026 at 10:30 PM
PolyBio scientific advisory board member Dr. William Eimer led the recent discovery of beta-amyloid & tau proteins’ antimicrobial activity targeting Herpes Simplex Virus 1 in the brain. (1/2)
The meeting highlighted NK-cell activating therapies—namely, Bioshield—which is undergoing investigation in two clinical trials for potential treatment efficacy in Long Covid.
January 31, 2026 at 8:46 PM
The meeting highlighted NK-cell activating therapies—namely, Bioshield—which is undergoing investigation in two clinical trials for potential treatment efficacy in Long Covid.
A key theme of the discussion centred around the long-term health implications of SARS-CoV-2 viral persistence, such as immune exhaustion.
January 31, 2026 at 8:46 PM
A key theme of the discussion centred around the long-term health implications of SARS-CoV-2 viral persistence, such as immune exhaustion.
PolyBio CEO Dr. Amy Proal & PolyBio-supported researchers Timothy Henrich MD & Steven Deeks MD recently presented data on Long Covid tissue findings at the inaugural USA-Saudi Biotech Alliance summit.
polybio.org/polybio-scie...
polybio.org/polybio-scie...
January 31, 2026 at 8:46 PM
PolyBio CEO Dr. Amy Proal & PolyBio-supported researchers Timothy Henrich MD & Steven Deeks MD recently presented data on Long Covid tissue findings at the inaugural USA-Saudi Biotech Alliance summit.
polybio.org/polybio-scie...
polybio.org/polybio-scie...
If you have been diagnosed with Long Covid & live in NYC, consider joining this first-of-a-kind trial. Email CoreResearch@MountSinai.org to see if you’re eligible.
January 27, 2026 at 6:29 PM
If you have been diagnosed with Long Covid & live in NYC, consider joining this first-of-a-kind trial. Email CoreResearch@MountSinai.org to see if you’re eligible.
Want first access to antiviral therapies for Long Covid? We’re looking for participants for a clinical trial of Truvada & Maraviroc. The trial is using cutting-edge biological markers including deep immune profiling & EndoPAT to determine efficacy of these medications in LC.
January 27, 2026 at 6:29 PM
Want first access to antiviral therapies for Long Covid? We’re looking for participants for a clinical trial of Truvada & Maraviroc. The trial is using cutting-edge biological markers including deep immune profiling & EndoPAT to determine efficacy of these medications in LC.
We’re also ecstatic about this mAb trial—hopefully we can fast-track some effective LC treatments via the help of the SPEAR working group.
January 21, 2026 at 8:03 PM
We’re also ecstatic about this mAb trial—hopefully we can fast-track some effective LC treatments via the help of the SPEAR working group.
8 “may provide an extremely promising route to stopping and perhaps reversing some of that damage. We as a group are thrilled to take this next step with Invivyd."
January 21, 2026 at 5:40 PM
8 “may provide an extremely promising route to stopping and perhaps reversing some of that damage. We as a group are thrilled to take this next step with Invivyd."
7/ “Chronic exposure to SARS-CoV- 2 spike protein in any form may be driving ongoing morbidity in America, and we believe the monoclonal antibodies discovered and developed by Invivyd…
January 21, 2026 at 5:40 PM
7/ “Chronic exposure to SARS-CoV- 2 spike protein in any form may be driving ongoing morbidity in America, and we believe the monoclonal antibodies discovered and developed by Invivyd…
6/ "The SPEAR Study Group and Invivyd have longstanding interest in clinical disease that can follow COVID infection and COVID vaccination,” said PolyBio CEO and SPEAR founding member Dr. Amy Proal.
January 21, 2026 at 5:40 PM
6/ "The SPEAR Study Group and Invivyd have longstanding interest in clinical disease that can follow COVID infection and COVID vaccination,” said PolyBio CEO and SPEAR founding member Dr. Amy Proal.
5/ The SPEAR working group, including core members of PolyBio Dr. Amy Proal, Or. David Putrino, Dr. Akiko Iwasaki, and Dr. Michael Peluso, has been crucial for the trial's design.
January 21, 2026 at 5:40 PM
5/ The SPEAR working group, including core members of PolyBio Dr. Amy Proal, Or. David Putrino, Dr. Akiko Iwasaki, and Dr. Michael Peluso, has been crucial for the trial's design.
4/ The trial will focus on patients with Long
COVID who demonstrate evidence of chronic infection or antigen persistence in a variety of tissues, and COVID vaccine-injured people, including those who have demonstrated persistence of vaccine-delivered spike protein.
COVID who demonstrate evidence of chronic infection or antigen persistence in a variety of tissues, and COVID vaccine-injured people, including those who have demonstrated persistence of vaccine-delivered spike protein.
January 21, 2026 at 5:40 PM
4/ The trial will focus on patients with Long
COVID who demonstrate evidence of chronic infection or antigen persistence in a variety of tissues, and COVID vaccine-injured people, including those who have demonstrated persistence of vaccine-delivered spike protein.
COVID who demonstrate evidence of chronic infection or antigen persistence in a variety of tissues, and COVID vaccine-injured people, including those who have demonstrated persistence of vaccine-delivered spike protein.
3/ VYD2311 may improve patient access to clinically significant mAb titres, due to its potential to be received intramuscularly.
January 21, 2026 at 5:40 PM
3/ VYD2311 may improve patient access to clinically significant mAb titres, due to its potential to be received intramuscularly.
2/ The novel monoclonal has demonstrated in vitro antiviral activity across all clinically recorded variants of SARS-CoV-2 tested since the original Wuhan strain, across many months of therapy.
January 21, 2026 at 5:40 PM
2/ The novel monoclonal has demonstrated in vitro antiviral activity across all clinically recorded variants of SARS-CoV-2 tested since the original Wuhan strain, across many months of therapy.
BREAKING: PolyBio Core Team Collaborating with Invivyd for Trial of the mAb VYD2311, Launching mid-2026
This week, Invivyd announced the upcoming launch of a new randomized, double-blind clinical trial of the monoclonal antibody WYD2311 in people with Long Covid and COVID vaccine injury.
This week, Invivyd announced the upcoming launch of a new randomized, double-blind clinical trial of the monoclonal antibody WYD2311 in people with Long Covid and COVID vaccine injury.
investors.invivyd.com
January 21, 2026 at 5:40 PM
BREAKING: PolyBio Core Team Collaborating with Invivyd for Trial of the mAb VYD2311, Launching mid-2026
This week, Invivyd announced the upcoming launch of a new randomized, double-blind clinical trial of the monoclonal antibody WYD2311 in people with Long Covid and COVID vaccine injury.
This week, Invivyd announced the upcoming launch of a new randomized, double-blind clinical trial of the monoclonal antibody WYD2311 in people with Long Covid and COVID vaccine injury.
Watch Dr. Mirabent’s full presentation here, from the PolyBio Fall 2025 Symposium: youtu.be/dGbb7UDcoHw?...
PolyBio Fall 2025 Symposium
YouTube video by PolyBio Research Foundation
youtu.be
January 12, 2026 at 10:58 PM
Watch Dr. Mirabent’s full presentation here, from the PolyBio Fall 2025 Symposium: youtu.be/dGbb7UDcoHw?...
2. Features of SARS-CoV-2-specific T cell responses. This includes identification of SCV2-specific T cells harboring public T cell receptors, and analysis of their clonal expansion histories.
Full project methodology: polybio.org/projects/sar...
Full project methodology: polybio.org/projects/sar...
January 12, 2026 at 10:58 PM
2. Features of SARS-CoV-2-specific T cell responses. This includes identification of SCV2-specific T cells harboring public T cell receptors, and analysis of their clonal expansion histories.
Full project methodology: polybio.org/projects/sar...
Full project methodology: polybio.org/projects/sar...
1. The extent and nature of SARS-CoV-2 persistence in different mucosal tissue compartments, the transcriptomes and proteomes of infected cells, and the global inflammatory state of surrounding cells.
January 12, 2026 at 10:58 PM
1. The extent and nature of SARS-CoV-2 persistence in different mucosal tissue compartments, the transcriptomes and proteomes of infected cells, and the global inflammatory state of surrounding cells.
PolyBio is supporting this extension to the LIINC collaborative to collect gut tissue and FRT biopsy samples from pre-menopausal women with and without Long Covid. Advanced technologies are analyzing the samples to determine: (cont. below)
January 12, 2026 at 10:58 PM
PolyBio is supporting this extension to the LIINC collaborative to collect gut tissue and FRT biopsy samples from pre-menopausal women with and without Long Covid. Advanced technologies are analyzing the samples to determine: (cont. below)
Their initial findings suggested SCV2 RNA and proteins can persist in the endometrium, endo-cervix and ecto-cervix; with more patient biopsies currently underway.
January 12, 2026 at 10:58 PM
Their initial findings suggested SCV2 RNA and proteins can persist in the endometrium, endo-cervix and ecto-cervix; with more patient biopsies currently underway.
“We found evidence of SARS-CoV-2 infected cells both in the gut and female reproductive tract… more than 4 years after the initial infection,” said Dr. Marta Mirabent, who is part of the Roan lab team investigating SCV2 persistence in these sites as driver of Long Covid.
January 12, 2026 at 10:58 PM
“We found evidence of SARS-CoV-2 infected cells both in the gut and female reproductive tract… more than 4 years after the initial infection,” said Dr. Marta Mirabent, who is part of the Roan lab team investigating SCV2 persistence in these sites as driver of Long Covid.
Reflecting on 2025, PolyBio helped lead the fight against Long Covid. We supported 6 clinical trials, started the Long Covid cure initiative, and began charting the route towards validated biomarkers. We’re looking forward to continuing to drive innovation for IACIs in 2026.
January 2, 2026 at 6:26 PM
Reflecting on 2025, PolyBio helped lead the fight against Long Covid. We supported 6 clinical trials, started the Long Covid cure initiative, and began charting the route towards validated biomarkers. We’re looking forward to continuing to drive innovation for IACIs in 2026.
Thank you to everyone who supported our work this year including donors, patients, and healthy controls in our trials.
#polybio2026countdown
#polybio2026countdown
January 1, 2026 at 12:26 AM
Thank you to everyone who supported our work this year including donors, patients, and healthy controls in our trials.
#polybio2026countdown
#polybio2026countdown